Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230399 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00230399 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 15 participants.
The verdict
NCT00230399, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will examine a new combination of drugs: celecoxib, capecitabine and irinotecan, for the treatment of metastatic colorectal cancer. Capecitabine and irinotecan, individually, are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of these two drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination of capecitabine and irinotecan has a positive effect on metastatic colorectal cancer. Likewise, previous research in animals has shown that celecoxib, a drug approved for arthritis therapy, also has activity against this tumor type and may improve the anti-cancer activity of the combination of capecitabine and irinotecan.
Interventions
- DRUG Capecitabine
- DRUG Celecoxib
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230399
The ClinicalTrials.gov registry entry for NCT00230399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT00230399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230399 about?
NCT00230399 is a clinical study titled "Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer". This study will examine a new combination of drugs: celecoxib, capecitabine and irinotecan, for the treatment of metastatic colorectal cancer. Capecitabine and irinotecan, individually, are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of these two ...
What is the current status of trial NCT00230399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2003-06. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00230399?
The interventions under investigation include: Capecitabine (DRUG), Celecoxib (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00230399?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.